Review Article

The Therapeutic Potential of Targeted Nanoparticulate Systems to Treat Rheumatoid Arthritis

Wenqing Liang,1 Yijun Yu,2 Zunyong Liu,1 Wenyi Ming,1 Hongming Lin,1 Hengguo Long2,1 and Jiayi Zhao1

1Department of Orthopaedics, Zhoushan Hospital of Traditional Chinese Medicine Affiliated to Zhejiang Chinese Medical University, Zhoushan 316000, China
2Medical Research Center, Zhoushan Hospital of Traditional Chinese Medicine Affiliated to Zhejiang Chinese Medical University, Zhoushan 316000, China

Correspondence should be addressed to Wenqing Liang; liangwq@usx.edu.cn, Hengguo Long; longhgzs@163.com, and Jiayi Zhao; zjy2038689@sina.com

Received 6 July 2022; Revised 13 August 2022; Accepted 30 August 2022; Published 12 October 2022

Academic Editor: Abdelwahab Omri

Copyright © 2022 Wenqing Liang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Rheumatoid arthritis (RA) is a widespread autoimmune inflammatory disease. It implicates damage to bones, cartilage, and joints with uncertain pathogenesis. It is coupled with an elevated risk of cardiovascular complications and human disability. The conventional dosage forms for RA treatment pose numerous problems including poor efficacy, large dosages, frequent administration, limited responsiveness, greater expenses, and severe side effects. The nanoparticulate systems are emerging as a new thought for the diagnosis and treatment of RA. Anti-inflammatory drug-loaded nanoparticulate systems aid in the active and passive targeting of the inflamed region. Improved bioavailability and targetability are achieved by using these systems. In this review, the pathophysiology of RA and its conventional treatment has been discussed. The role of various nanoparticulate systems for passive and active targeting of RA has been reviewed. The authors have summarized the current practices in the typical and novel nanosystems to improve the quality of life in RA patients.

1. Introduction

Arthritis is characterized as the inflammation of one or more joints [1]. There are several signs and symptoms of the disease that include redness of the joints, swelling of the joint and joint discomfort, and joint warmth [2]. Rheumatoid arthritis (RA) and osteoarthritis (OA) are the most frequent forms of arthritis. OA is caused by mechanical wear and tear on joints while RA is classified as an autoimmune disorder [3, 4]. RA tends to impact numerous joints of the body. If left untreated, RA damages bone and cartilage, which makes it difficult for patients to do daily tasks like working or going to social gatherings. This condition is called chronic RA [5]. Figure 1 represents the manifestation of types of arthritis joints. When the tendon is inflamed (tenosynovitis), it results in both the loss of cartilage and the erosion of bone [6]. RA has a heterogeneous clinical response to the different treatments [7]. RA affects around 5 out of every 1000 people and tragically, 80 percent of those affected face disability within 20 years after the early symptoms.

There are several antiarthritic medications on the market today and most of them are relatively expensive, have limited efficacy, and/or have unavoidable adverse effects. Inflammatory drugs are one of the most expensive treatment categories for health care [9]. Nonsteroidal anti-inflammatory drugs (NSAIDs), glucocorticoids (GCs), disease-modifying antirheumatic drugs (DMARDs), and biological agents are widely prescribed to treat RA. NSAID-induced nephrotoxicity, liver damage, and heart failure are all potential side effects of these treatments, despite their ability to slow the progression of the disease [10, 11]. If medication continues to be ineffective, the only other option is surgery [12–14].

An effective alternative to these outdated therapeutic procedures is required. This review has been focused on
novel strategies to treat RA. The role of nanotechnology-based nanoparticulate systems will be discussed. The lipid, polymer, metal, inorganic nonmetal, and bionic technology-based nanoparticulate systems will be elaborated. Current progress in different nanodrug delivery systems to treat RA will also be highlighted.

2. Role of Nanoparticulate Systems in RA Treatment

Nanotechnology has revolutionized every field of applied science. Nanoparticulate systems have attracted attention for their potential to explore a variety of anti-inflammatory drug-loaded nano formulations [15]. Table 1 includes some of the nanoparticulate systems reported for the treatment of RA.

Many researchers have been working on the development of various nanoparticulate systems for treating RA by either directly or indirectly targeting the area of inflammation. Improved bioavailability, targetability, and enhanced therapeutic action are the main advantages of these systems. Prolonged circulation time is achieved by pegylated nanoparticulate systems. Additionally, smart nanoparticulate systems have been designed that release the therapeutic agent only when a trigger or stimulation is encountered. The graphical representation of such systems has been represented in Figure 2. Mahtab et al. discovered the enhanced permeability and retention (EPR) effect that provided a crucial push intended for extensive research into the application of nanoparticulate systems. Passive targeting mainly depends on the EPR effect. Angiogenesis (newly created blood vessels) is critical in chronic inflammatory diseases like RA because of local hypoxia and growth factor generation at inflamed joints. Active targeting following systemic delivery can be accomplished by coating nanoparticulate systems with a targeting moiety. As the disease progresses, angiogenesis and inflammation are the most prominent features. Growth factors, cytokines, adhesion molecules, and proteases have all been implicated in the formation of angiogenesis in various ways. The vascular endothelial growth factor (VEGF) and angiopoietin play a key function in the hypoxia-VEGF system. The endothelial cell surface is also overexpressed with many adhesion molecules, including integrin v3, E-selectin, vascular cell adhesion molecule-1 (VCAM-1), and intercellular cell adhesion molecule-1. Inflamed synovial membranes are rich in macrophages, which have a wide range of proinflammatory properties and contribute significantly to inflammation and joint damage. The selective delivery of nanomedicine by binding to a specific receptor could switch off their complicated connections with other cells and improve the condition of RA while preserving the basic functions of resting macrophages. CD44, CD64, folate receptor-beta (FR-), vasoactive intestinal peptide (VIP) receptor, scavenger receptor class A, toll-like receptors, transforming growth factor-beta receptors, etc. were observed to be over-expressed on activated macrophages [31]. The antibodies or other specialized adhesion molecules (e.g., selectins) are bound to the surface of nanoparticulate systems [32]. Redox-responsive clustered Fe₃O₄ nanoparticles (NPs) were produced in a study. Fe₃O₄-based nanoclusters (NCs) of these NPs were produced following laser irradiation to exhibit adjustable r1 and r2 relativities, thereby enabling enhanced dual-mode T1/T2-weighted MR imaging of inflammatory arthritis [33].

3. Synthetic Nanoparticulate Systems

Based on the particle integrity, the synthetic nanoparticulate systems can be categorized into two major categories: the nonrigid nanoparticles, which include liposomes and solid
| Nanoparticulate system | Drug | In vivo model | Outcome | Ref |
|------------------------|------|--------------|---------|-----|
| Liposome (nonrigid nanoparticulate system) | Dexamethasone | Rats with adjuvant-induced arthritis | Significantly down-regulated serum proinflammatory cytokines including tumor necrosis factor-α and interleukin-1β when compared to free dexamethasone | [16] |
| Liposome/gold nanoparticles (hybrid nanoparticulate system) | Ubiquinone | Mice with collagen-induced arthritis | Proinflammatory cytokines were significantly decreased | [17] |
| Calcium phosphate/liposome-based nanocarrier (hybrid nanoparticulate system) | siRNA and methotrexate (MTX) | Mice model | Blocked the transcription factor NF-κB and reduced the expression of proinflammatory cytokines | [18] |
| Solid lipid nanoparticles (nonrigid nanoparticulate system) | β-Sitosterol | Complete Freund adjuvant (CFA)-induced arthritis via a dual pathway in rats | Increased the redox status of synovium (reduced the malonaldehyde (MDA) and increase superoxide dismutase (SOD), glutathione (GSH), and catalase (CAT)) levels, and reduced the cytokines such as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), IL-2, 6, 16, and 17 and increased level of IL-10, transforming growth factor beta (TGF-β). Reduced the level of cyclooxygenase-2 (COX-2), prostaglandin E2 (PGE2), vascular endothelial growth factor (VEGF), and NF-κB. | [19] |
| Chitosan-coated solid lipid nanoparticles (hybrid nanoparticulate system) | Leflunomide | Rats with adjuvant-induced arthritis | Improved joint healing and reduced hepatotoxicity | [20] |
| Chitosan and hyaluronic acid-based polymeric nanoparticles (rigid nanoparticulate system) | Antibodies | Biological assays | Selectively captured and inactivated the proinflammatory cytokine IL-6 | [21] |
| Ethyl cellulose and Eudragit S-100-based polymeric nanoparticles (rigid nanoparticulate system) | Mefenamic acid | In vitro drug release | Greater stability and controlled drug release for 12 h. | [22] |
| Poly(lactic-co-glycolic acid) (PLGA)–PEG–folic acid (FA), sodium deoxycholate (SDC), and solutol HS15 (HS15) nanocarriers (rigid nanoparticulate system) | Germacrone | Adjuvant-induced arthritis (AIA) rats | Levels of proinflammatory cytokines (TNF-α, IL-1β) in the rat’s inflammatory tissue were significantly reduced | [23] |
| Polyethylene-glycol (PEG)-fabricated multiwalled carbon nanotubes (rigid nanoparticulate system) | Corticosteroids (triamcinolone) | Biological assays | Specifically targeted cells homing to or present in arthritic joints | [24] |
| Single-walled carbon nanotubes (rigid nanoparticulate system) | Targeted carrier | K/BxN serum transfer (STA) model | Significantly inhibited the inflammatory response of fibroblast-like synoviocytes | [25] |
| Hyaluronate-gold nanoparticle/tocilizumab (HA-AuNP/TCZ) complex (rigid nanoparticulate system) | Tocilizumab (monoclonal antibody) | Collagen-induced arthritis (CIA) model mice by ELISA | Reduced levels of inflammatory cell infiltration and cartilage and bone destruction | [26] |
| Multifunctional dendrimer-entrapped gold nanoparticles (rigid nanoparticulate system) | Codelivery of antioxidant alpha-tocopheryl succinate (α-TOS) and anti-inflammatory anti-TNF-α siRNA | CIA mouse model | Better antioxidative effect and the most significant decrease of mRNA of TNF-α and TNF-α protein in the ankle joints | [27] |
| Nanoparticulate system                                      | Drug                                      | In vivo model          | Outcome                                                                 | Ref  |
|-----------------------------------------------------------|-------------------------------------------|------------------------|-------------------------------------------------------------------------|------|
| Folate/RGD-dual-functionalized mesoporous silica nanoparticles (rigid nanoparticulate system) | Polydatin                                 | CIA model              | Joint damages were significantly improved                              | [28] |
| Biomimetic exosome (bionic)                               | Glucocorticoids (dexamethasone sodium phosphate (Dex) nanoparticle (Exo/Dex)) | In vitro study and CIA mice | Enhanced endocytosis and excellent anti-inflammation effect against RAW264.7 cells and in vivo model significantly reduced inflamed joints | [29] |
| Metabolically engineered exosomes (bionic)                | Engineered exosomes as a next generation drug for RA | CIA mice model         | Promoted M1-M2 macrophage polarization in the bone marrow regions of joints inflamed by RA and reduced the activity of surrounding proinflammatory cells, such as M1 macrophages, activated synovial fibroblasts, and TH17 cells | [30] |
lipid nanoparticles, and the rigid nanoparticles, which include polymeric nanoparticles and nanoparticles made of inorganic materials.

3.1. Nonrigid Nanoparticulate Systems. It is well-known that nonrigid nanoparticulate systems have relatively soft structures that are easily disrupted by an external force. The nonrigid nanoparticulate systems include liposomes and solid lipid nanoparticulate systems (SLNs). Nonrigid nanoparticulate systems have an important role in the treatment of RA.

3.1.1. Liposomes. Liposomes are derived from the Greek words “lipo” and “soma,” which mean “fat” and “body,” respectively. Dr. Alec Bangham and Dr. Horne pioneered the concept of liposomes in 1964. Liposomes are vesicles that can hold hydrophilic (water-soluble) drugs, hydrophobic drugs (water-insoluble), peptides, and nucleic acids effectively. It is possible to compartmentalize a variety of drugs in a single formulation using liposomes. Vesicles made up of lipids and cholesterol are safe, nontoxic, noncarcinogenic, nonthrombogenic, and biodegradable in the natural environment [35].

The targeted delivery of various drugs can minimize their side effects. Methotrexate (MTX) is a commonly prescribed medication for the treatment of RA. MTX was loaded with higher encapsulation efficiency in liposomes (>30%). Experiments in arthritic animals demonstrate that liposomes encapsulating MTX considerably boosted the biological effect [36]. Similar results have been reported with polymerized stealth liposomes as a delivery system for the enhanced anti-inflammatory effect of dexamethasone for the treatment of RA. It was shown that the polymerized stealth liposomes remained stable in blood vessels for a substantial amount of time. Cells were able to metabolize these without inflicting any serious damage. Upon injection into arthritic rats, polymerized stealth liposomes with dexamethasone displayed prolonged circulation and accumulated primarily in the affected joints. The in vivo animal study confirmed suppressing of the proinflammatory cytokines (TNF-α and IL-1A) in joint tissues, thereby, decreasing joint swelling, and slowing down the progression of RA [37]. In another study, folate conjugated double liposomes containing prednisolone and MTX were used to target RA. The folate receptor is well-known to be expressed at a higher level in inflamed cells than in normal cells. Both drugs were shown to have a larger concentration in inflamed joints than in noninflamed joints [38]. The thermosensitive liposomes can further enhance the targeted drug delivery. Sinomenine hydrochloride (SIN-TSL) was loaded into a unique thermosensitive liposome created using a pH gradient technique. When the temperature was increased from 37 to 43°C, the rate of drug release was significantly faster than at 37°C. SIN-TSL with microwave hyperthermia increased anti-RA effects in both in vitro and animal studies [39].

T-helper type-17 (Th17) cells are dramatically increased by the proinflammatory cytokine interleukin-23 (IL-23) in the conditions like RA. Biofunctionalized liposomes were studied by Lima et al. to deliver anti-IL-23 antibodies (Abs) effectively. Systemic administration of Abs is limited by the risk of significant side effects and the short half-life of these Abs. A liposomal immobilization technique was used to improve the therapeutic efficacy of anti-IL-23 Abs. Because of the anti-inflammatory and antioxidant capabilities, gold nanoparticulate systems (AuNPs) were loaded into...
cytes (FLS) have been identified as a powerful activator of miR-23a, which improves the focused therapeutic effect of prednisolone in RA by producing tumor-like growth and the production of pannus in the joints. Berberine (BBR) has recently been discovered to be a highly effective method of delivering an adjuvant-induced arthritic disease model. Using guinea pig skin placed on a modified Franz diffusion cell, the in vitro penetration of piroxicam through the SLN-based nanoparticulate system was evaluated. SLN formulations showed improved skin permeability. The FDA has approved leflunomide (LEF) for use in the treatment of RA. However, a wide range of gastrointestinal side effects, including nausea, diarrhea, vomiting, and stomatitis have been attributed to oral LEF treatment. After the application of chitosan (CS) on the surface of the SLNs, folic acid was added (FA). As compared to oral LEF suspension in rats with adjuvant-induced arthritis (AIA), the oral treatment of FA-CS-SLNs resulted in increased joint healing and decreased hepatotoxicity.

The SLNs provide oral as well as topical drug delivery. Piroxicam is an effective anti-inflammatory, antipyretic, and analgesic medication; nevertheless, its oral administration for extended periods is limited due to a variety of gastrointestinal adverse effects. SLNs containing piroxicam were prepared using the solvent emulsification/evaporation process. Using guinea pig skin placed on a modified Franz diffusion cell, the in vitro penetration of piroxicam through the SLN-based nanoparticulate system was evaluated. SLN formulations showed improved skin permeability. The high-melting fat matrix-based SLNs are being developed to overcome the limitations of conventional colloidal carriers including liposomes and polymeric nanoparticulate systems. Colloidal drug delivery technologies such as SLNs have been shown to improve drug entrapment, bioavailability, and pharmacokinetic characteristics of hydrophilic and hydrophobic drugs.

The targeted drug delivery with minimal burst release has been achieved with the SLNs. Piperine-loaded SLN dispersion to maximize its oral and topical effectiveness was reported. The prepared SLN was given orally and topically to rats with CFA-induced arthritis. Piperine from the SLN gel formulation accumulated in the skin, according to ex vivo results utilizing the Franz diffusion cell. The pharmacodynamic study results revealed that both topical and oral piperine elicited a substantial response when compared to chloroquine suspension administered orally. The FDA has approved leflunomide (LEF) for use in the treatment of RA. However, a wide range of gastrointestinal side effects, including nausea, diarrhea, vomiting, and stomatitis have been attributed to oral LEF treatment. After the application of chitosan (CS) on the surface of the SLNs, folic acid was added (FA). As compared to oral LEF suspension in rats with adjuvant-induced arthritis (AIA), the oral treatment of FA-CS-SLNs resulted in increased joint healing and decreased hepatotoxicity.

The SLNs may have an edge over other types of nanoparticulate systems because of their high biocompatibility, increased drug loading capacity, and scalability. The drawbacks of the conventional nanocarriers include polymer degradation and cytotoxicity; lack of suitable large-scale production process; insufficient stability; drug leakage and fusion; phospholipid degradation; high production cost; and sterilization problems. The high-melting fat matrix-based SLNs are being developed to overcome the limitations of conventional colloidal carriers including liposomes and polymeric nanoparticulate systems. Colloidal drug delivery technologies such as SLNs have been shown to improve drug entrapment, bioavailability, and pharmacokinetic characteristics of hydrophilic and hydrophobic drugs.

3.1.2. SLNs. There has been an enormous amount of attention paid to SLNs since their introduction in 1991, and they have been used as a highly effective method of delivering medications and DNA and targeting therapies [43]. SLNs are made of a solid lipid core, such as triglyceride or stearic acid, as well as waxes and emulsifiers. Numerous methods were studied for the preparation of SLNs, e.g., solvent emulsification/evaporation approach [44, 45]. SLNs may have an advantage over other types of nanoparticulate systems because of their high biocompatibility, increased drug loading capacity, and scalability. The drawbacks of the conventional nanocarriers include polymer degradation and cytotoxicity; lack of suitable large-scale production process; insufficient stability; drug leakage and fusion; phospholipid degradation; high production cost; and sterilization problems. The high-melting fat matrix-based SLNs are being developed to overcome the limitations of conventional colloidal carriers including liposomes and polymeric nanoparticulate systems [46]. Figure 3 represents the difference between the liposomes and the SLNs and the advantages of the SLNs. Colloidal drug delivery technologies such as SLNs have been shown to improve drug entrapment, bioavailability, and pharmacokinetic characteristics of hydrophilic and hydrophobic drugs.

The targeted drug delivery with minimal burst release has been achieved with the SLNs [43, 48]. Piperine-loaded SLN dispersion to maximize its oral and topical effectiveness was reported. The prepared SLN was given orally and topically to rats with CFA-induced arthritis. Piperine from the SLN gel formulation accumulated in the skin, according to ex vivo results utilizing the Franz diffusion cell. The pharmacodynamic study results revealed that both topical and oral piperine elicited a substantial response when compared to chloroquine suspension administered orally [49]. The FDA has approved leflunomide (LEF) for use in the treatment of RA. However, a wide range of gastrointestinal side effects, including nausea, diarrhea, vomiting, and stomatitis have been attributed to oral LEF treatment. After the application of chitosan (CS) on the surface of the SLNs, folic acid was added (FA). As compared to oral LEF suspension in rats with adjuvant-induced arthritis (AIA), the oral treatment of FA-CS-SLNs resulted in increased joint healing and decreased hepatotoxicity [20].

The SLNs provide oral as well as topical drug delivery. Piroxicam is an effective anti-inflammatory, antipyretic, and analgesic medication; nevertheless, its oral administration for extended periods is limited due to a variety of gastrointestinal adverse effects. SLNs containing piroxicam were prepared using the solvent emulsification/evaporation process. Using guinea pig skin placed on a modified Franz diffusion cell, the in vitro penetration of piroxicam through the SLN-based nanoparticulate system was evaluated. SLN formulations showed improved skin permeability [50]. Curcumin (CUR) is a natural product that has anti-inflammatory properties. Jeevana and Muni developed SLNs to increase the solubility of CUR. The CUR content of SLNs...
was reported to be 98.7-99.3%. These results indicated minimal CUR loss during the SLN production process. Ex vivo tests on goat skin showed that SLN topical gel released a significant amount of CUR (76.93%) within 30 minutes of being applied to the skin membrane. Similarly, in the in vivo application, an X-ray radiographic study of untreated rats revealed abnormalities in the hind paws. The treatment with CUR-SLNs prevented these deformities and significantly reduced paw edema in the treated rats [51].

3.2. Rigid Nanoparticulate Systems. Rigid nanoparticles have been shown to have a higher mechanical strength than non-rigid lipid-based nanoparticles published thus far. Rigid nanoparticles are classified into these key subcategories: biodegradable polymeric nanoparticles, carbon nanotubes, and metallic and inorganic nanoparticles.

3.2.1. Polymeric Nanoparticulate (PNP). Solid nanoparticulate, core-shell structures, polymeric micelles, and polypelexes are all examples of biodegradable PNP formulations. Nanoparticulate formulation and synthesis methods are dependent on the polymer and cargo characteristics; however, PNP is most often generated via self-assembly or emulsion in most cases. PNP Polymers may be assembled in a variety of ways, including the formation of complexes of cationic polymers with anionic nucleic acids, as well as the spontaneous formation of micelles when the concentration of amphiphilic block copolymers reaches a threshold micelle concentration. Nanoparticulate may also be created by procedures such as emulsification, in which droplets of one phase are disseminated in another. Solubilized in an organic phase, polymers are often combined with surfactants and ultrasonicated at high power in an aqueous solution to produce nanodroplets [52]. Hardened polymer nanoparticles are formed when the solvent evaporates from the emulsion. They may also be encased in another material to create core-shell nanoparticulate with desirable surface features [53]. PNP is divided into two main categories: Polysaccharides and proteins produced from natural sources. Peptides and polysaccharides may be degraded in the body using enzymes and the breakdown rate can be controlled to get the desired release profile. Dextran, gelatin, poly(L-lysine), chitosan, and alginate are among them [21, 54]. The delivery channels and disease targets may all benefit from synthetic polymers that have desired features such as hydrophobicity and degradation profile. Poly(Lactide-co-Glycolide), poly(ε-caprolactone), sugar cyclodextrins, and poly(-amino ester) are examples of these polyesters [55].

There are a variety of ways to deliver drugs for the treatment of RA. Targeted drug administration based on stimuli is the most prevalent method. Stimuli from the micro- or macroenvironment can alter the physical properties of stimulus-sensitive polymers [56]. Polymer transitions are influenced by factors such as solubility, hydrophilic/lipophilic balance, solvent interactions, and conductivity. These changes are driven by chemical reactions including acid-base interaction, redox, thermal, or hydrolysis of compounds linked to the polymer chain [57].

pH shift has been used to cause the release of integrated therapeutics whenever environmental changes are related to pathophysiological processes such as inflammation [58]. In this context, the idea of using pH-sensitive PNP-carrying therapeutic compounds (NSAIDs, GCS) in RA treatment has great potential. The enhanced angiogenesis that occurs in RA leads to the discontinuity of inflammatory endothelium cells and an increase in vascular permeability. This abnormality may allow nanosystems of the appropriate size to successfully enter inflamed joints [59]. Following enhanced delivery of anti-RA drugs via nanoparticulate systems, low pH vicinity causes the drug to be delivered directly into the affected area of the body. Using this approach, it is possible to increase the efficacy of RA therapeutics by increasing therapeutic selectivity and reducing systemic side effects. Dexamethasone- (DEX-) loaded HAPNPs (HA-coated acid-sensitive PNP) were examined by Yu et al., for the treatment of RA. PCADK, a polyketide with a high degree of acid sensitivity, was used to make the acid-sensitive polymeric material that comprised egg phosphatidylcholine, polyethyleneimine, and PCADK. As a result of its ability to bind CD44, HA was chosen as a targeting moiety. An average diameter of 150.5 nm was shown to have a pH-dependent drug release characteristic in the nanoparticulate system. HAPNPs demonstrated a strong ability to target activated macrophages because of the presence of HA on the nanoparticulate systems, as demonstrated by cellular uptake experiments. It was also shown that HAPNPs/DEX treatment reduced inflammatory cell infiltration, bone degradation, and cartilage damage in the ankle joints of rat models of AIA [60].

The phase-transition behavior of temperature-responsive polymers is considered while selecting these materials. Polymers with a lower critical solution temperature (LCST) for whom the solubility is influenced by temperature changes are widely used to develop nanocarriers with thermoresponsive properties. Transitional polymers become more soluble, and their components swell due to hydrogen interactions between water molecules and the polymer functional groups. This property makes these polymers suitable for loading drugs below the LCST. During the shift from hydrophilic to hydrophobic, a morphological change occurs from the coil to the globule, due to a change in the temperature. During this transition, the hydrogen bonds and network collapse, resulting in the polymer being insoluble and the water molecules being squeezed out of the polymer. The guest drug molecules are released because of this transformation. Figure 4 depicts the mechanism of action of thermoresponsive drug delivery systems [61].

Drug administration via photo-responsive polymers is based on their ability to absorb light. Upon exposure to light, these polymers change phase. The moieties are responsive to UV, visible, and near-infrared light. These materials are appealing because of their water solubility, biodegradability, and biocompatibility, as well as their ability to manage the spatial and temporal triggering of drug release. Two basic tactics may be utilized depending on the application: one time or repeated on-off active compound release. This is plausible because some materials, when exposed to light,
can undergo irreversible structural changes, while others when the trigger is removed, can return to their former state [62]. Fomina et al. used a self-immolating quinone-methide system to create degradable nanoparticulate systems made of photo-sensitive polymers. The new photo-sensitive nano system initiated the release of tiny hydrophobic compounds in a controlled burst. As a result of the system’s adaptable architecture, the triggering group was responsive to both internal and external stimuli, which offered a lot of promise for RA therapy. Authors of another study described a polymeric substance that was exposed to two-photon absorption, and disassembled in response to near-infrared irradiation, at biologically tolerable levels. Many pendants’ protective 4-bromo7-hydroxycoumarin groups were photolyzed, starting a chain reaction that finally destroyed the polymer’s backbone by cyclization and rearrangement [63].

Redox-sensitive nanoparticulate systems are another area of interest in the search for new ways to deliver drugs. People’s interest in this type of system has been sparked by the redox potential difference between the oxidizing and reducing compartments. Reactive oxygen species (ROS) have a critical role in the pathophysiology of chronic inflammatory arthropathies like RA. ROS are created mostly during oxidative phosphorylation, although they may also be formed during an oxidative burst by activated phagocytic cells. They act as a key intracellular signal that boosts the inflammatory response [8]. Pu et al. reported chitosan-based nanoparticles with dual responses to oxidative stress and reduced pH for curcumin release and its anti-inflammatory applications. This occurred because curcumin and the carrier had Förster resonance energy transfer. It also allowed us to keep tabs on how the intracellular release was progressing. Upon activation, curcumin might effectively neutralize excess oxidants generated by macrophages that had been activated with lipopolysaccharide (LPS). The anti-inflammatory properties of curcumin-loaded nanoparticles were tested on LPS-induced ankle inflammation in a mouse model [64].

3.2.2. Carbon Nanotubes and Nanohorns. Carbon nanotubes (CNTs) are made up of sheets of six-membered carbon atom rings that have been folded into cylinders. Single-walled carbon nanotubes (SWCNTs) have just one layer, whereas multiwalled carbon nanotubes (MWCNTs) have two or more layers (MWCNTs). CNTs are also known as cup-stacked carbon nanotubes and carbon nanohorns [65]. These enticing carbon nanostructures are now being used in a variety of medication delivery methods for the treatment of life-threatening disorders. CNTs have been used to treat inflammatory illnesses like RA, according to many studies.

Kayat et al. investigated the use of folate-anchored CNT’s to target an antirheumatoid disease, (MTX), to the arthritic inflammatory region. In comparison to naked MWCNTs packed with MTX, as well as free MTX, folate-conjugated MWCNTs significantly enhanced percentage inhibition of RA, biological half-life, and MTX delivery rate. The recent results show that drug-loaded functional MWCNTs may change pharmacokinetics while also providing a steady and optimal drug delivery mechanism [66].

A small interfering RNA (siRNA) targeting the NOTCH1 gene was investigated as a therapeutic carrier for MTX in HiPco- and carboxyl-SWCNTs made by Andersen et al. MTX was covalently attached to the nanotubes after they had been solubilized with PEGylation. A serum transfer mouse model showed that SWCNTs mainly accumulated in joints that were inflamed. They found that both SWCNTs were related to B cells, monocytes, and neutrophils in the blood. Adding MTX to SWCNTs reduced their ability to target immune cells, particularly B cells; however, siRNA alone boosted their ability to target immune cells. Targeting specificity to neutrophils and monocytes was increased when both MTX and siRNA were loaded into carboxyl-SWCNTs, but not to B cells. It was possible to alter the targeting specificity by changing the ratio of MTX and siRNA on SWCNTs [67].

3.2.3. Metallic Nanoparticulate Systems. Metal nanoparticulate have outstanding characteristics, may have numerous functional groups added to them, and are frequently employed in biological applications [68]. Kim et al. developed manganese ferrite and ceria nanoparticle-anchored mesoporous silica nanoparticles (MFC–MSNs) to cure RA. Degenerative features were reduced in the CIA rat model when MFC–MSNs were injected intra-articularly. They have a synergistic effect on scavenging ROS and producing O2, and they may reduce M1 macrophages while polarising M2 macrophages. Furthermore, as a delivery vehicle, monodisperse silica nanospheres may continuously release MTX, enhancing the therapeutic impact as shown in Figure 5 [69].
In another study, Kalashnikova et al. created albumin-cerium oxide nanoparticulate that were indocyanine green conjugated (ICG). The nanoparticulate systems were put into the CIA mice’s swollen joints, and an in vivo imaging system showed that they accumulated in the affected joints and had a stronger therapeutic impact. This unique albumin-cerium oxide nanoparticulate targeting and therapeutic impact point us to a new route for arthritis therapy [70]. Lee et al. created a hyaluronate–gold nanocarriers/tocilizumab (HA-AuNP/TCZ) as a combination therapy for RA. In this treatment, AuNP was exploited as a therapeutic carrier that reduced angiogenesis. TCZ is a monoclonal antibody that binds against the interleukin-6 (IL-6) receptor that is exploited as an immunosuppressive treatment in the initiation and progression of RA by interfering with IL-6. HA is well-known for its cartilage-protecting and lubricating qualities. End-group thiolated HA was synthesized by altering HA with cystamine by reductive amination, which was then reduced with dithiothreitol (DTT) (HA-SH) (HA-SH). HA-SH was utilized to chemically modify AuNP, whereas TCZ was utilized to physically modify it. In collagen-induced arthritis, the therapeutic effect of the HA-AuNP/TCZ combination on RA was verified [26].

3.2.4. Inorganic Non-metallic Nanomaterials. One of the most often used RA drug delivery techniques is based on injectable silica-based nanoparticulate systems. By using a core–cone structure, Li et al. produced mesoporous silica nanoparticulate systems (MSN-CC) as more convenient, efficient, and long-lasting therapeutic than the previous method of injecting HA. In a rat model of RA, this nanomaterial enhanced the synthesis of HA, reduced synovitis inflammation, and promoted bone repair. Hyaluronan synthase type 2 (HAS2) has high protein loading capacity and good biocompatibility, degradation, and degradability. Functionalized group PEI was applied to the surface of mesoporous silica to load and deliver HAS2. Intra-articular injection of MSN-CC-PEI successfully transported HAS2 into synovial cells and boosted the production of endogenous HA both inside and outside the body [71]. Local percutaneous injection and nano-controlled MTX release were studied by Guo et al. The MTX-mSiO2@PDA system was highly responsive in terms of pH. After 24 hours, the cumulative amount of MTX transferred from MTX-mSiO2@PDA to pH 5.0 receptor fluid via the entire skin was nearly three times larger than the amount transferred to pH 7.4 receptor fluid in vitro local percutaneous injection studies. Further in vivo testing in DBA/1 mice utilizing a CIA paradigm found that the thickness of a mouse’s toes fell to roughly 65 percent of its initial level after 27 days of local percutaneous MTX-mSiO2@PDA injection. It was shown that the toe thickness variation of mice administered with MTX-
mSiO2@PDA through local percutaneous injection was substantially lower than that of animals given MTX directly [72].

4. Bionic Nanomaterials

Bionics is the study of biologically inspired engineering-based materials and their applications [73]. The application of bionics in nano drug delivery systems has revolutionized the field of biomaterials. Despite successful PEGylation and phospholipid modification, synthetic nanoparticulate systems that persist in living animals quickly elicit an immunological response, followed by fast immune system eradication. Thus, the application of bionics for the bio interfacing strategy to enable prolonged circulation time has gained much importance. Cell membrane-coated and exosomes-encapsulated nanoparticulate systems have found a prominent place in novel drug delivery systems.

4.1. Cell Membrane-Based Nanoparticulate Systems. The nanoparticulate systems have grown in popularity in recent years, in part due to the similarity they have with real biological systems. An endogenous cell membrane (e.g., macrophage) is used as a functional material on the surface of the nanoparticulate systems to minimize immunogenicity and extend blood circulation duration [74]. These systems certainly inherit the antigenic surface and associated membrane functions, such as chemotaxis to inflamed regions and cytokine neutralization, from their source cells. Macrophages and neutrophils are important innate immune cells in the human body. These cells are involved in the body’s inflammatory response. These can cause synovial hyperplasia i.e., the release of a variety of degrading enzymes, cartilage degradation, and the production of inflammatory factors [75]. Immune cells are widely used to synthesize biomimetic nanoparticulates with anti-inflammatory properties. Biohybrid delivery systems can be constructed using a range of natural cells, including red blood cells, platelets, immune cells, malignant cells, and even E. coli, as the membrane source [76]. As a result, immune cells are frequently employed to synthesize biomimetic nanoparticulate systems with anti-inflammation characteristics. Recently, a variety of natural cells, including red blood cells, platelets, immunological cells, malignant cells, and even E. coli, have been produced [77]. The nanoparticulate systems described above have also been reported with cell membrane coating to be utilized as biomaterials. Figure 6 represents the application of cell membranes to encapsulate the nanoparticles.

Macrophage cell membranes based on porous silicon nanoparticulate systems (Psi) have been described as composite platforms for the treatment of RA by Fontana et al. Macrophages (KG-1) were employed as model cells for the vesicles’ membrane cytoplasmic membrane. The PSi@KG-1 nanoparticulate system did not activate the immune system in KG-1 macrophages, and covering UnTHCPSi particles with cell membranes decreased their immunostimulatory activity [79]. Similarly, nanoparticles coated with macrophage-derived microvesicles have been shown to target RA. The monocytes’ intrinsic ability to target inflammation motivated the development of macrophage-derived microvesicle-coated nanoparticulate systems (MMV-coated nanoparticulate systems, MNP) for the treatment of RA. The MMV was generated through the application of a novel strategy. It was found that the application of cytochalasin B (CB)
increased MMV secretion by loosening the macrophages’ cytoskeleton-to-membrane link. The MMV proteome profile was examined using iTRAQ (isobaric tags for relative and absolute quantitation). This suggests that MMV has similar bioactivity to RA-targeting macrophages, based on its membrane proteins. Microparticles were examined both in vitro and in vivo after being coated with MMV and poly (lactic-co-glycolic acid) (PLGA) nanoparticulate systems. In vitro, MNP bound to inflamed HUVECs much more strongly than the red blood cell membrane-coated nanoparticulate systems (RNP). In a CIA mouse model, MNP showed a much greater ability to target compared to bare NP and RNP. In a proteomic investigation, Mac-1 and CD44 were found to have a significant role in the MNP’s unique capacity to target. T-RNP-encapsulated Tacrolimus (a model medicine) greatly slowed the progression of the disease in mice. As a potential and plentiful source of macrophage-mimicking material, MMV has been demonstrated in this study to be an effective biomimetic vehicle for RA targeting and treatment [80]. A platelet membrane is also applied to the nanoparticles to treat RA with them. For the treatment of RA, platelet-mimetic nanoparticulate systems (PNPs) were produced that mimic the structure of platelets. Poly(lactic-co-glycolic acid) nanoparticulate systems (PNPs) were coated with a whole platelet membrane by platelet receptor-mediated adhesion, resulting in PNPs having a wide range of functional receptors. The platelet membrane covering the nanoparticulate systems made them more stable and better suited for passive targeting. Using P-selectin and GVPI recognition, the authors were able to increase PNP binding to inflamed endothelium in vitro and accumulation in joints of a CIA animal model of RA. It was demonstrated that PNPs might have targeted RA tissues similar to natural platelets via several routes. As an added benefit, PNPs were implanted with the model drug FK506, which was then administered to patients with RA [81]. According to a study by Zhang et al., nanoparticulate systems coated with a neutrophil membrane were found to be effective in reducing joint damage and inflammation in patients with RA. Nanoparticulate systems are covered with neutrophil membranes by fusing the membranes to polymeric cores. The antigenic exterior and related membrane activities of the parent cells were carried over into these nanoparticulate systems, making them ideal decoys for biological agents that target neutrophils. Proinflammatory cytokines were neutralized, synovial inflammation was reduced, and the nanoparticulate systems penetrated deep into the cartilage matrix to give significant chondroprotection against joint damage. Human transgenic mice were used to study the efficiency of neutrophil membrane-coated nanoparticulate systems in treating arthritis, which was shown to lessen joint damage and the severity of arthritis in mice produced by collagen [82].

4.2. Exosomes Encapsulated Nanoparticulate Systems. Exosomes are small intracellular membrane-based vesicles of varying compositions that participate in a variety of biological and pathological processes. Exosomes have significant advantages over other nanoparticulate drug delivery technologies such as liposomes and polymeric nanoparticulate systems in that they are nonimmunogenic due to their similar composition to the body’s cells [83, 84]. Glucocorticoids (GCs) have a powerful antirheumatoid effect. However, their clinical applicability is limited due to nonspecific distribution after systemic administration, as well as significant adverse responses after long-term treatment. Exosomes are newly applied for the treatment of RA and much less research work is done yet.

Yan et al. reported exosome-derived biomimetic nanoparticulate systems targeted to inflamed joints for improved RA treatment. Glucocorticoids (GCs) are highly effective in the treatment of RA (RA). However, clinical applicability is constrained by their nonspecific distribution following systemic administration and the possibility of major adverse effects with long-term administration. To improve treatment and minimize side effects, the authors developed a biomimetic exosome (Exo) encapsulating dexamethasone sodium phosphate (Dex) nanoparticulate systems (Exo/Dex), the surface of which was modified with a folic acid (FA)-polyethylene glycol- (PEG-) cholesterol (Chol) compound to achieve an FPC-Exo/Dex active targeting drug delivery system. By inhibiting pro-inflammatory cytokines and enhancing anti-inflammatory cytokines, this approach demonstrated increased endocytosis and an effective anti-inflammatory impact against RAW264.7 cells in vitro. Further, biodistribution studies revealed that FPC-Exo/Dex fluorescence intensity was greater than that of other Dex formulations in joints, implying that it accumulates more readily at inflammatory sites. FPC-Exo/Dex preserved the bone and cartilage of CIA mice better and dramatically reduced inflammatory joints in an in vivo biodistribution trial. Following that, in vivo safety evaluations revealed that this biomimetic drug delivery system exhibited minimal hepatotoxicity and an acceptable level of biocompatibility [29].

5. Conclusions and Future Perspective

RA is an autoimmune musculoskeletal condition that has resulted in significant disability in individuals and has a global influence on people’s life. Thus, efficient treatment of RA is critical for relieving patients’ discomfort and increasing the cure rate. Nanotechnology has been applied for RA treatment. Nanoparticulate systems have significantly improved the targeted drug delivery and enhanced in vitro and in vivo effects of drugs with reduced side effects has been achieved successfully. Although nanotechnology is in its infancy, it has the potential to improve disease diagnosis, treatment, and research. The commercial and service industries’ performance validates the idea that nanotechnology would someday play a substantial role in clinical practice. Nanotechnology can dramatically lower the cost of many existing therapies and enable a variety of creative applications and reduce the negative effects. Nanotechnology enables more precise treatment techniques, which may result in more effective and durable implants, lower infection rates, and enhanced bone and tendon healing. The theoretical benefits of nanomedicine are beginning to be realized,
particularly in the realm of immune disorders as well, because of massive fundamental scientific research efforts. However, additional research is necessary to fully understand the safety and usefulness of this innovative technology. As the advances in medical understanding and technology could lead to new treatment options in the future, there are certain limitations as well. Even though NPS has demonstrated numerous advantages in drug delivery, some issues must be addressed before clinical application may proceed. As the liposomes have been utilized in clinical for drug delivery, most drug toxicities have been reduced when they are coated with liposomes; however, it is not the optimal vehicle for water-soluble medicines. As for metal carrier, many are not stable, which limit their application, e.g., zinc oxide. Similarly, CNT is a potential vehicle with outstanding biocompatibility, but it must be improved in its capacity to target specific cells. Therefore, reducing biological toxicity and maintaining their targeting and bioimaging ability are the future directions in drug delivery. A better understanding of anti-inflammatory disorders and focused usage of nanoparticulate systems for diverse diseases would significantly increase treatment effects and lessen the adverse effects.

Ethical Approval

This study does not involve any animals or humans studies.

Consent

All authors approved the final version of the manuscript.

Conflicts of Interest

All the authors declare that they have no financial or any other competing interests.

Authors’ Contributions

Wenqing Liang, Hengguo Long, and Jiayi Zhao prepared the draft and wrote the manuscript. Yijun Yu and Zunyong Liu helped in preparing the figures. Wenyi Ming and Hongming Lin refined and arranged the contents of the manuscript. All authors approved the final manuscript. Wenqing Liang and Yijun Yu contributed equally to this work.

Acknowledgments

This work was supported by the Public Technology Applied Research Projects of Zhejiang Province (LGF22H060023 to WQL), the Medical and Health Research Project of Zhejiang Province (2022KY433 to WQL), the Traditional Chinese Medicine Science and Technology Projects of Zhejiang Province (2022ZB382 to WQL and JYZ), and the Research Fund Projects of The Affiliated Hospital of Zhejiang Chinese Medicine University (2021FSYYZY45 to WQL).

References

[1] Y. Chow and K. Chin, “The role of inflammation in the pathogenesis of osteoarthritis,” *Mediators of Inflammation*, vol. 2020, Article ID 8293921, 19 pages, 2020.
[2] J. Y. Ng and A. M. Azizuddin, “Rheumatoid arthritis and osteoarthritis clinical practice guidelines provide few complementary and alternative medicine therapy recommendations: a systematic review,” *Clinical Rheumatology*, vol. 39, no. 10, pp. 2861–2873, 2020.
[3] T. Woo, L. Lau, N. Cheng, P. Chan, K. Tan, and A. Gardner, “Efficacy of oral collagen in joint pain-osteoarthritis and rheumatoid arthritis,” *Journal of Arthritis*, vol. 6, 2017.
[4] J. R. Chua, S. Jamal, M. Riad et al., “Disease burden in osteoarthritis is similar to that of rheumatoid arthritis at initial rheumatology visit and significantly greater six months later,” *Arthritis & Rheumatology*, vol. 71, no. 8, pp. 1276–1284, 2019.
[5] Q. Guo, Y. Wang, D. Xu, J. Nossent, N. J. Pavlos, and J. Xu, “Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies,” *Bone Research*, vol. 6, 2018.
[6] Y.-J. Lin, M. Anzaghe, and S. Schülke, “Update on the pathomechanism, diagnosis, and treatment options for rheumatoid arthritis,” *Cells*, vol. 9, no. 4, p. 880, 2020.
[7] P. Conigliaro, P. Triggianese, E. de Martino et al., “Challenges in the treatment of rheumatoid arthritis,” *Autoimmunity Reviews*, vol. 18, no. 7, pp. 706–713, 2019.
[8] L. J. S. da Fonseca, V. Nunes-Souza, M. O. F. Goulart, and L. A. Rabelo, “Oxidative stress in rheumatoid arthritis: what the future might hold regarding novel biomarkers and add-on therapies,” *Oxidative Medicine and Cellular Longevity*, vol. 2019, Article ID 7536805, 16 pages, 2019.
[9] I. Khilfeh, E. Guyette, J. Watkins, D. Danielson, D. Gross, and K. Yeung, “Adherence, persistence, and expenditures for high-cost anti-inflammatory drugs in rheumatoid arthritis: an exploratory study,” *Journal of Managed Care and Specialty Pharmacy*, vol. 25, no. 4, pp. 461–467, 2019.
[10] O. Köhler-Forsberg, C. N. Lydholm, C. Hjorthøj, M. Nordentoft, O. Mors, and M. E. Benros, “Efficacy of anti-inflammatory treatment on major depressive disorder or depressive symptoms: meta-analysis of clinical trials,” *Acta Psychiatrica Scandinavica*, vol. 139, no. 5, pp. 404–419, 2019.
[11] P. Tziona, P. Theodosis-Nobelo, and E. A. Rekka, “Medicinal chemistry approaches of controlling gastrointestinal side effects of non-steroidal anti-inflammatory drugs. Endogenous protective mechanisms and drug,” *Medicinal Chemistry*, vol. 13, pp. 408–420, 2017.
[12] C. Maglio, M. Peltonen, A. Rudin, and L. M. S. Carlsson, “Bariatric surgery and the incidence of psoriasis and psoriatic arthritis in the Swedish obese subjects study,” *Obesity*, vol. 25, no. 12, pp. 2068–2073, 2017.
[13] B. Young, S. Watson, J. Perez, G. McGwin, J. A. Singh, and B. A. Ponce, “Trends in joint replacement surgery in patients with rheumatoid arthritis,” *The Journal of Rheumatology*, vol. 45, no. 2, pp. 158–164, 2018.
[14] A. Ganehwa, R. Wu, M. Chae et al., “Failure rates of base of thumb arthritis surgery: a systematic review,” *The Journal of Hand Surgery*, vol. 44, no. 9, pp. 728–741.e10, 2019.
[15] M. Rabiei, S. Khashanian, S. S. Samavati, H. Derakhshankah, S. Jamasb, and S. J. P. McIntnes, “Nanotechnology application in drug delivery to osteoarthritis (OA), rheumatoid arthritis (RA), and osteoporosis (OSP),” *Journal of Drug Delivery Science and Technology*, vol. 61, article 102011, 2021.
M. Jia, C. Deng, J. Luo et al., “A novel dexamethasone-loaded liposome alleviates rheumatoid arthritis in rats,” International Journal of Pharmaceutics, vol. 540, no. 1–2, pp. 37–64, 2018.

J. Jhun, J. Moon, J. Ryu et al., “Liposome/gold hybrid nanoparticle encoded with CoQ10 (LGNP-CoQ10) suppressed rheumatoid arthritis via STAT3/Thr17 targeting,” PLoS One, vol. 15, no. 11, article e0241080, 2020.

W. Duan and H. Li, “Combination of NF-kB targeted siRNA and methotrexate in a hybrid nanocarrier towards the effective treatment in rheumatoid arthritis,” Journal of Nanobiotechnology, vol. 16, no. 1, pp. 1–9, 2018.

F. Zhang, Z. Liu, X. He, Z. Li, B. Shi, and F. Cai, “β-Sitosterol-loaded solid lipid nanoparticles ameliorate complete Freund’s adjuvant-induced arthritis in rats: involvement of NF-kB and HO-1/Nrf-2 pathway,” Drug Delivery, vol. 27, no. 1, pp. 1329–1341, 2020.

M. Zewail, “Folic acid decorated chitosan-coated solid lipid nanoparticles for the oral treatment of rheumatoid arthritis,” Therapeutic Delivery, vol. 12, no. 4, pp. 297–310, 2021.

A. C. Lima, C. Cunha, A. Carvalho, H. Ferreira, and N. M. Neves, “Interleukin-6 neutralization by antibodies immobilized at the surface of polymeric nanoparticles as a therapeutic strategy for arthritic diseases,” ACS Applied Materials and Interfaces, vol. 10, no. 16, pp. 13839–13850, 2018.

A. Krishna Sailaja and V. Sree Lola, “Formulation of mefename acid loaded polymeric nanoparticles for the treatment of rheumatoid arthritis,” Journal of Bionanoscience, vol. 12, no. 2, pp. 177–183, 2018.

T. Tan, Q. Huang, W. Chu et al., “Delivery of gemcramone (GER) using macrophages-targeted polymeric nanoparticles and its application in rheumatoid arthritis,” Drug Delivery, vol. 29, no. 1, pp. 692–701, 2022.

Y. K. Lee, J. K. Choi, Y. J. Kang et al., “Triamcinolone–carbon nanotube conjugation inhibits inflammation of human arthritis synovial fibroblasts,” Journal of Materials Chemistry B, vol. 4, no. 9, pp. 1660–1671, 2016.

S.-C. Hung, N. Rajasekaran, S. Zhu, Z. Ma, E. Ghosn, and E. D. Melins, “Single-walled carbon nanotubes target neutrophils and Ly-6Chi monocytes and localize to joints in murine models of arthritis,” The Journal of Immunology, vol. 200, 1 Supplement, 2018.

H. Lee, M. Y. Lee, S. H. Bhang et al., “Hyaluronate–gold nanoparticle/tolizilumab complex for the treatment of rheumatoid arthritis,” ACS Nano, vol. 8, no. 5, pp. 4790–4798, 2014.

J. Li, L. Chen, X. Xu et al., “Targeted combination of antioxidative and anti-inflammatory therapy of rheumatoid arthritis using multifunctional dendrimer-entrapped gold nanoparticles as a platform,” Small, vol. 16, no. 49, article 2005661, 2020.

X. Deng, K. Hou, L. Yang et al., “A folate/RGD-dual-functionalized mesoporous silica nanoparticles targeting GABA-p38 MAPK-MRTFs/SRF signaling pathway in rheumatoid arthritis,” Clinical and Translational Medicine, vol. 11, no. 5, 2021.

F. Yan, Z. Zhong, Y. Wang et al., “Exosome-based biomimetic nanoparticles targeted to inflamed joints for enhanced treatment of rheumatoid arthritis,” Journal of Nanobiotechnology, vol. 18, no. 1, pp. 1–15, 2020.

D. G. You, G. T. Lim, S. Kwon et al., “Metabolically engineered stem cell–derived exosomes to regulate macrophage heterogeneity in rheumatoid arthritis,” Science Advances, vol. 7, no. 23, 2021.

A. Mahtab, S. Rabbani, Y. Neupane et al., “Facile functionalization of teriflunomide-loaded nanoliposomes with chondroitin sulphate for the treatment of rheumatoid arthritis,” Carbohydrate Polymers, vol. 250, 2020.

W. Ulbrich and A. Lampecht, “Targeted drug-delivery approaches by nanoparticulate carriers in the therapy of inflammatory diseases,” Journal of The Royal Society Interface, vol. 7, Supplement 1, 2010.

D. Ma, M. Shi, X. Li et al., “Redox-sensitive clustered ultrasmall iron oxide nanoparticles for switchable T2/T1-weighted magnetic resonance imaging applications,” Bioconjugate Chemistry, vol. 31, no. 2, pp. 352–359, 2020.

L. Liu, W. Guo, and X. J. Liang, “Move to nano-arthrology: targeted stimuli-responsive nanomedicines combat adaptive treatment tolerance (ATT) of rheumatoid arthritis,” Biotechnology Journal, vol. 14, no. 1, article 1800024, 2019.

S. A. Roberts, N. Parikh, R. J. Blower, and N. Agrawal, “Spin: rapid synthesis, purification, and concentration of small drug-loaded liposomes,” Journal of Liposome Research, vol. 28, no. 4, pp. 331–340, 2018.

D. Guimarães, J. Noro, A. Loureiro et al., “Increased encapsulation efficiency of methotrexate in liposomes for rheumatoid arthritis therapy,” Biomedicines, vol. 8, 2020.

Q. Wang, L. He, D. Fan, W. Liang, and J. Fang, “Improving the anti-inflammatory efficacy of dexamethasone in the treatment of rheumatoid arthritis with polymerized stealth liposomes as a delivery vehicle,” Journal of Materials Chemistry B, vol. 8, 2020.

A. Verma, A. Jain, A. Tiwari et al., “Folate conjugated double liposomes bearing prednisolone and methotrexate for targeting rheumatoid arthritis,” Pharmaceutical Research, vol. 36, no. 8, 2019.

Q. Shen, X. Zhang, J. Qi, G. Shu, Y. Du, and X. Ying, “Sinomine hydrochloride loaded thermosensitive liposomes combined with microwave hyperthermia for the treatment of rheumatoid arthritis,” International Journal of Pharmaceutics, vol. 576, 2020.

A. Lima, C. Campos, C. Cunha et al., “Biofunctionalized Liposomes to Monitor Rheumatoid Arthritis Regression Stimulated by Interleukin-23 Neutralization,” Advanced Healthcare Materials, vol. 10, no. 2, article 2001570, 2021.

V. M. Gouveia, J. Lopes-De-Araújo Ujo, S. A. C. Lima, C. Nunes, and S. Reis, “Hyaluronic acid-conjugated pH-sensitive liposomes for targeted delivery of prednisolone on rheumatoid arthritis therapy,” Future Medicine, vol. 13, no. 9, pp. 1037–1049, 2018.

S. Sujitha, P. Dinesh, and M. Rasool, “Berberine encapsulated PEG-coated liposomes attenuate Wnt1/β-Catenin signaling in rheumatoid arthritis via miR-23a activation,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 149, 2020.

V. Mishra, K. Bansal, A. Verma et al., “Solid lipid nanoparticles: emerging colloidal nano drug delivery systems,” Pharmaceutics, vol. 10, no. 4, 2018.

G. Zheng, M. Zheng, B. Yang, H. Fu, and Y. Li, “Using doxorubicin loaded solid lipid nanoparticles: synthesis of a novel arginine-glycine-aspartic tripeptide conjugated, pH sensitive lipid and evaluation of the nanomedicine in vitro and in vivo,” Biomedicine & Pharmacotherapy, vol. 116, 2019.

E. Nemati, A. Mokhtarzadeh, V. Panahi-Azar et al., “Ethambutol-loaded solid lipid nanoparticles as dry powder inhalable
formulation for tuberculosis therapy,” AAPS PharmSciTech, vol. 20, no. 3, 2019.

[46] R. K. Tekade, R. Maheshwari, M. Tekade, and M. B. Chougule, “Solid lipid nanoparticles for targeting and delivery of drugs and genes,” in Nanotechnology-Based Approaches for Targeting and Delivery of Drugs and Genes, pp. 256–286, Elsevier, 2017.

[47] Y. Mirchandani, V. B. Patravale, and S. Brijesh, “Solid lipid nanoparticles for hydrophilic drugs,” Journal of Controlled Release, vol. 335, pp. 457–464, 2021.

[48] A. Akladyl, H. O’Mary, S. Valdes et al., “Lipid nanoparticles with minimum burst release of TNF-α siRNA show strong activity against rheumatoid arthritis unresponsive to methotrexate,” Journal of Controlled Release, vol. 283, pp. 280–289, 2018.

[49] M. R. Bhalekar, A. R. Madgulkar, P. S. Desale, and G. Marium, “Formulation of pipeline solid lipid nanoparticles (SLN) for treatment of rheumatoid arthritis,” Drug development and industrial pharmacy, vol. 43, no. 6, pp. 1003–1010, 2017.

[50] S. Mohammad-Samani, S. Zoiaji, and E. Entezar-Ahmadi, “Piroxicam loaded solid lipid nanoparticles for topical delivery: preparation, characterization and in vitro permeation assessment,” Journal of Drug Delivery Science and Technology, vol. 47, pp. 427–433, 2018.

[51] J. Jyothi B and M. Lakshmi K, “Pharmacodynamic activity of curcumin gels produced from curcumin solid lipid nanoparticles (SLN) for rheumatoid arthritis,” International Research Journal of Pharmacy, vol. 8, no. 5, pp. 88–94, 2017.

[52] R. L. McCall and R. W. Sirianni, “PLGA nanoparticles formed by single- or double-emulsion with vitamin E-TPGS,” Journal of Visualized Experiments: JoVE, vol. 82, no. 82, article 51015, 2013.

[53] Y. Wang, S. Gao, W. H. Ye, H. S. Yoon, and Y. Y. Yang, “Co-delivery of drugs and DNA from cationic core-shell nanoparticles self-assembled from a biodegradable copolymer,” Nature Materials, vol. 5, no. 10, pp. 791–796, 2006.

[54] P. Allawadhi, V. Singh, K. Govindaraj et al., “Biomedical applications of polysaccharide nanoparticles for chronic inflammatory disorders: focus on rheumatoid arthritis, diabetes and organ fibrosis,” Carbohydrate polymers, vol. 281, 2022.

[55] Y. K. Sung and S. W. Kim, “Recent advances in polymeric drug delivery systems,” Biomaterials Research, vol. 24, no. 1, pp. 1–12, 2020.

[56] P. I. Siafaka, N. Ü. Okur, E. Karavas, and D. N. Bikiaris, “Surface modified multifunctional and stimuli responsive nanoparticles for drug targeting: current status and uses,” International Journal of Molecular Sciences, vol. 17, no. 9, 2016.

[57] H. Priya James, R. John, A. Alex, and K. R. Anoop, “Smart polymers for the controlled delivery of drugs – a concise overview,” Acta Pharmacuetica Sinica B, vol. 4, no. 2, pp. 120–127, 2014.

[58] M. Karimi, M. Eslami, P. Sahandi-Zangabad et al., “pH-Sensitive stimulus-responsive nanocarriers for targeted delivery of therapeutic agents,” Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology, vol. 8, no. 5, pp. 696–716, 2016.

[59] S. M. Peper, R. Lew, T. Mikuls et al., “Rheumatoid arthritis treatment after methotrexate: the durability of triple therapy versus etanercept,” Arthritis Care & Research, vol. 69, no. 10, pp. 1467–1472, 2017.

[60] C. Yu, X. Li, Y. Hou et al., “Hyaluronic acid coated acid-sensitive nanoparticles for targeted therapy of adjuvant-induced arthritis in rats,” Molecules, vol. 24, no. 1, 2019.

[61] M. Karimi, P. S. Zangabad, A. Ghasemi et al., “Temperature-responsive smart nanocarriers for delivery of therapeutic agents: applications and recent advances,” ACS Applied Materials & Interfaces, vol. 8, no. 33, pp. 21107–21133, 2016.

[62] X. Lin, C. T. Tsao, M. Kyomoto, and M. Zhang, “Injectable Natural Polymer Hydrogels for Treatment of Knee Osteoarthritis,” Advanced Healthcare Materials, vol. 11, 2021.

[63] N. Fomina, C. L. McFearin, M. Sermsakdi, J. M. Morachis, and A. Almutairi, “Low power, biologically benign NIR light triggers polymer disassembly,” Macromolecules, vol. 44, no. 21, pp. 8590–8597, 2011.

[64] H. L. Pu, W. L. Chiang, B. Maiti et al., “Nanoparticles with dual responses to oxidative stress and reduced pH for drug release and anti-inflammatory applications,” ACS Nano, vol. 8, no. 2, pp. 1213–1221, 2014.

[65] N. Saito, H. Haniu, Y. Usui et al., “Safe clinical use of carbon nanotubes as innovative biomaterials,” Chemical Reviews, vol. 114, no. 11, pp. 6040–6079, 2014.

[66] J. Kayat, N. K. Mehra, V. Gajbiye, and N. K. Jain, “Drug targeting to arthritic region via folate appended surface-engineered multi-walled carbon nanotubes,” Journal of Drug Targeting, vol. 24, no. 4, pp. 318–327, 2016.

[67] C. Kofoed Andersen, S. Khatri, J. Hansen et al., “Carbon nanotubes-potent carriers for targeted drug delivery in rheumatoid arthritis,” Pharmaceutics, vol. 13, no. 4, 2021.

[68] M. C. Edmundson, M. Capeness, and L. Horsfall, “Exploring the potential of metallic nanoparticles within synthetic biology,” New Biotechnology, vol. 31, no. 6, pp. 572–578, 2014.

[69] J. Kim, H. Y. Kim, S. Y. Song et al., “Synergistic oxygen generation and reactive oxygen species scavenging by manganese ferrite/ceria co-decorated nanoparticles for rheumatoid arthritis treatment,” ACS Nano, vol. 13, no. 3, pp. 3206–3217, 2019.

[70] I. Kalashnikova, S. J. Chung, M. Nafuijman et al., “Ceria-based nanotheranostic agent for rheumatoid arthritis," Theranostics, vol. 10, no. 26, pp. 11863–11880, 2020.

[71] H. Li, H. Guo, C. Lei et al., “Nanotherapy in joints: increasing endogenous hyaluronan production by delivering hyaluronan synthase 2,” Advanced Materials, vol. 31, no. 46, article 1904535, 2019.

[72] T. Guo, X. Kang, S. Ren, X. Ouyang, and M. Chang, “Construction of a nano-controlled release methotrexate delivery system for the treatment of rheumatoid arthritis by local percutaneous administration,” Nanomaterials, vol. 11, no. 11, article 1282, 2021.

[73] “Twenty-first century’s fuel sufficiency roadmap-steve esomba, Dr. - Google Books,” November 2021, https://books.google.com.pk/books?id=W6DFBgaAQBAJ&lpg=PA644&ots=u_Vt-ceEvU&dq=%22bionical+creativity+engineering%22&pg=PA644#v=onepage&q=%22bionical+creativityengineering%22&f=false.

[74] R. J. Berckmans, R. Nieuwland, M. C. Kraan et al., “Synovial microparticles from arthritic patients modulate chemokine and cytokine release by synoviocytes,” Arthritis Research & Therapy, vol. 7, no. 3, article R536, 2005.

[75] J. Li, X. Zhen, Y. Lyu, Y. Jiang, J. Huang, and K. Pu, “Cell membrane coated semiconducting polymer nanoparticles for enhanced multimodal cancer phototheranostics,” ACS Nano, vol. 12, no. 8, pp. 8520–8530, 2018.

[76] J. Dalli, T. Montero-Melendez, L. V. Norling et al., “Heterogeneity in neutrophil microparticles reveals distinct proteome
and functional properties,” *Molecular & Cellular Proteomics*, vol. 12, no. 8, pp. 2205–2219, 2013.

[77] M. Xuan, J. Shao, and J. Li, “Cell membrane-covered nanoparticles as biomaterials,” *National Science Review*, vol. 6, no. 3, pp. 551–561, 2019.

[78] Y. Wang, P. Zhang, Y. Wei et al., “Cell-membrane-display nanotechnology,” *Advanced Healthcare Materials*, vol. 10, no. 1, article 2001014, 2021.

[79] F. Fontana, S. Albertini, A. Correia et al., “Bioengineered porous silicon nanoparticles@macrophages cell membrane as composite platforms for rheumatoid arthritis,” *Advanced Functional Materials*, vol. 28, no. 22, article 1801355, 2018.

[80] R. Li, Y. He, Y. Zhu et al., “Route to rheumatoid arthritis by macrophage-derived microvesicle-coated nanoparticles,” *Nano Letters*, vol. 19, no. 1, pp. 124–134, 2019.

[81] Y. He, R. Li, J. Liang et al., “Drug targeting through platelet membrane-coated nanoparticles for the treatment of rheumatoid arthritis,” *Nano Research*, vol. 11, no. 11, pp. 6086–6101, 2018.

[82] Q. Zhang, D. Dehaini, Y. Zhang et al., “Neutrophil membrane-coated nanoparticles inhibit synovial inflammation and alleviate joint damage in inflammatory arthritis,” *Nature Nanotechnology*, vol. 13, no. 12, pp. 1182–1190, 2018.

[83] G. Wu, J. Zhang, Q. Zhao et al., “Molecularly engineered macrophage-derived exosomes with inflammation tropism and intrinsic heme biosynthesis for atherosclerosis treatment,” *Angewandte Chemie-International Edition*, vol. 59, no. 10, pp. 4068–4074, 2020.

[84] E. J. Bunggulawa, W. Wang, T. Yin et al., “Recent advancements in the use of exosomes as drug delivery systems 06 biological sciences 0601 biochemistry and cell biology,” *Journal of Nanobiotechnology*, vol. 16, no. 1, pp. 1–13, 2018.